Glioblastoma Idh-wildtype

• CLINICAL_TRIALS trial_result · 2026-04-24
  Clinical Trial Update: Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma [Phase 1]

  A Phase 1 trial evaluating Triapine in combination with radiation therapy for recurrent glioblastoma or astrocytoma has been suspended.

• CLINICAL_TRIALS trial_result · 2026-04-13
  Clinical Trial Update: Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas [Phase 1, Phase 2]

  Clinical trial update on a phase 1/2 study evaluating retifanlimab with or without difluoromethylornithine for progressive high-grade glioma…

• CLINICAL_TRIALS trial_result · 2026-03-17
  Clinical Trial Update: Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas [EARLY_Phase 1]

  Clinical trial update describing a Phase 0 study with expansion evaluating quisinostat plus radiotherapy in newly diagnosed and recurrent Gr…

• CLINICAL_TRIALS trial_result · 2026-01-14
  Clinical Trial Update: Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma [Phase 1]

  Phase 1 trial evaluating mycophenolate mofetil in combination with standard of care for glioblastoma; study status is ACTIVE_NOT_RECRUITING.

• CLINICAL_TRIALS trial_result · 2026-01-09
  Clinical Trial Update: Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients [Phase 1]

  A Phase 1 trial evaluating regorafenib plus temozolomide with or without radiotherapy in MGMT-methylated, IDH-wildtype glioblastoma has comp…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2026-01-02
  Clinical Trial Update: Study of Niacin in Glioblastoma [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating niacin for glioblastoma (IDH-wildtype) is currently suspended.

• CLINICAL_TRIALS trial_result · 2025-12-18
  Clinical Trial Update: Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter [Phase 2]

  A Phase 2 trial evaluating ropidoxuridine as a radiosensitizer in newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter …

• CLINICAL_TRIALS trial_result · 2025-11-10
  Clinical Trial Update: Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma [NA]

  Mayo Clinic sponsors a clinical trial evaluating continuous glucose monitoring to manage hyperglycemia in patients with glioblastoma (IDH-wi…

• CLINICAL_TRIALS trial_result · 2025-03-13
  Clinical Trial Update: Biomolecular Analysis for Predicting Response to Regorafenib [NA]

  Completed clinical trial evaluating biomolecular markers to predict which glioblastoma patients respond to regorafenib, including the IDH-wi…